Glenmark Pharmaceuticals Ltd News

Glenmark Pharma share price up 2% on rolling out Lacosamide oral solution

The uptick in Glenmark Pharmaceuticals share price came after the company announced the launch of Lacosamide Oral Solution, 10 mg/mL

Nifty Pharma jumps over 2%: Analysts decode the drivers behind the rally

Individually, Cipla soared up to 3.68 per cent to hit an intraday high of Rs 1,547.70 per share, while Sun Pharma soared up to 3.30 per cent to hit an intraday high of Rs 1,791.60 per share

Glenmark Pharma Q2 profit rises on strong India business performance

The company also reported a 14.6 per cent rise in revenues in the European market to Rs 687.4 crore, while recording a 1.2 per cent revenue drop in the North America market

Glenmark Pharma Q2 results: PAT rises to Rs 354 cr on chronic drugs demand

The drugmaker reported a consolidated profit of Rs 354 crore (nearly $42 million) for the quarter ended Sept. 30, compared with a loss of Rs 81.95 crore a year ago

Q2 results today: Hero MotoCorp, HAL, Glenmark among 1,181 to post earnings

Q2 results today, November 14: Lemon Tree Hotels, Bharat Forge, Grasim Industries, Muthoot Finance, and Medanta to post Q2FY25 earnings on Thursday

Glenmark arm recalls two products in US due to manufacturing issues

Drug firm Glenmark is recalling two products in the US due to manufacturing issues, according to the US Food and Drug Administration. New Jersey-based Glenmark Pharmaceuticals Inc, USA, a unit of Mumbai-based Glenmark Pharmaceuticals, is recalling 45,504 bottles of Ryaltris (olopatadine hydrochloride and mometasone fluorate) Nasal Spray. The company is recalling the affected lot due to "defective delivery system", the US Food and Drug Administration (USFDA) said in its latest enforcement report. "The dip tube is clogged causing the spray not to work," it added. Glenmark Pharmaceuticals Inc, USA, initiated the nationwide (US) Class II recall on September 24 this year. As per the USFDA, a Class II recall is initiated in a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote. The US health regulator said the drug firm is also ...

This Ashish Dhawan-backed pharma stock zoomed over 100% in 2 straight years

Glenmark Pharma rallied nearly 9% to Rs 1,763.90 after the US drug regulator issued Form 483 with zero observations for its formulation manufacturing facility in Aurangabad.

Glenmark to pay $25 million as part of settlement with US authorities

Glenmark Pharmaceuticals has agreed to pay USD 25 million as part of a settlement with the US Department of Justice regarding a case related to the pricing of a generic drug. Glenmark Pharmaceuticals Inc, USA, a wholly-owned subsidiary of the Mumbai-based drug maker, has agreed to pay the amount in six installments over five years, with interest on the settlement amount at a rate of 4.25 per cent per annum from May 28, 2024, the company said in a late night regulatory filing on Wednesday. The Civil Division of the US Department of Justice has concluded its False Claims Act and Anti-Kickback Statute investigation in a settlement with Glenmark Pharmaceuticals Inc, USA, it said. "The settlement amount and interest on the settlement amount constitute restitution," the drug maker said. As noted, the settlement does not contain any admission of liability by the company, except to the extent already admitted by Glenmark in the August 2023 Deferred Prosecution Agreement, it added. Last ye

F&O Cues: Nifty needs to hold above 24,650; check bullish, bearish stocks

Derivatives market update: FIIs reduced longs in index futures marginally on Monday; their index long-short ratio stands at 1:1. Retail traders up long bets.

Here's why Glenmark Pharma stock hit all time high on Aug 19; details here

The rise in the share price came after the company announced that its unit, Glenmark Therapeutics Inc, USA (Glenmark) has launched Olopatadine Hydrochloride Ophthalmic Solution USP, 0.1 per cent.

Glenmark Pharma hits lifetime high on steady Q1 show; Ebitda soars 34% YoY

Glenmark Pharmaceuticals stock surged up to 5.68 per cent, hitting its all time high at Rs 1,576 per share on the NSE in Friday's intraday trade

Glenmark Pharma Q1 results: Profit increases to Rs 462 cr on strong demand

The drugmaker reported consolidated profit before exceptional items and taxes of Rs 462 crore ($55 million) for the quarter ended June 30, from Rs 203 crore a year ago

Q1FY25 results today: Glenmark Pharma among over 400 firms to post earnings

Q1FY25 company results: Cosco India, Bajaj Healthcare, Reliance Infrastructure, and Coffee Day Enterprises will be releasing their quarter results on Aug 14

Pharma shares rally; Suven, Granules, Ajanta, Jubilant surge over 5%

Q1 earnings cheer: Lupin, Zydus Lifesciences, Glenmark Pharmaceuticals, Aurobindo Pharma, Torrent Pharmaceuticals and Sun Pharmaceutical were up between 2 per cent and 3 per cent.

Glenmark Pharma receives USFDA approval for seizure treatment drug

The approval by the US Food & Drug Administration (USFDA) is for Topiramate capsules of strengths 15 mg and 25 mg, Glenmark Pharmaceuticals said in a statement